2023 Annual Report

ULP 2023 Resident Companies

Developing muscle regenerative treatments using stem cells and gene editing technologies for Limb-girdle Muscular Dystrophies.

ACGENE Lab

AVITA Medical Americas

Regenerative medicine company with a technology platform to address unmet medical needs in therapeutic skin restoration. Developing the infrastructure for remote patient monitoring for telemedicine services.

AYA Digital

Technology for noninvasive measurement of blood glucose will allow both spot check and continuous measurement of blood sugar.

Cercacor

Small molecule drug discovery company focused on developing novel therapeutic approaches for diseases related to fatty acid metabolism. Developing a benchtop, integrated cell sorting platform for life science research spanning oncology, neurology, and other areas of biomedical research.

Crescenta Biosciences

CytoRecovery

ElectroNucleics

Development of a manufacturable prototype device.

EndoCyclic Therapeutics

Developing the first non-hormonal, disease-modifying therapeutic for endometriosis.

Engineering Extracellular Vesicles (EVs) derived from stem cells to target auto immune diseases such as psoriasis, multiple sclerosis, and COPD.

Entelexo Biotherapeutics

Equilibr.io

Developing innovative approach to biosensors.

Primarily focused on developing anti-cancer drugs, anti diabetic drugs, anti-alcoholic liver disease drugs, and other health products. Conducting translational biospecimen research services towards cancer therapeutic research initiatives with a goal of improving patient care and outcomes.

Fulgent Life

Hoag

Kalman

Developing novel and cutting edge biologics.

Leonhardt's Launchpads

Organ regeneration based on bioelectric controlled protein expressions and biologics.

37 University Lab Partners 2023 Annual Report | Breakthroughs Today, Careers Tomorrow

Made with FlippingBook - Online catalogs